Final Results Support Pembrolizumab as Standard of Care in MSI-H/dMMR Metastatic Colorectal Cancer
Pembrolizumab improved progression-free survival but not overall survival.
Gastrointestinal Cancers News
GASTROINTESTINAL CANCER ADVISOR
Gastrointestinal Cancers News
Capecitabine Maintenance Improves Progression-Free Survival in Metastatic Colorectal Cancer
There was no improvement in overall survival.
Panitumumab Plus 5FU/LV: ‘Preferred’ Maintenance Regimen in RAS Wild-Type Metastatic Colorectal Cancer
Adding panitumumab to 5-fluorouracil and leucovorin improved progression-free survival.
Nivolumab-Based Regimens May Be New Standard of Care in Advanced Esophageal Squamous Cell Carcinoma
Two nivolumab-based regimens improved survival over chemotherapy alone.
Perioperative Chemotherapy Matches Neoadjuvant Multimodal Therapy for Esophageal Cancer
Researchers found that CROSS is not inferior to MAGIC/FLOT, supporting it’s place in decision making for patients with locally advanced esophageal cancer.
Data Support Nivolumab Plus Chemo as Standard First-Line Therapy for Advanced Gastric, Esophageal Cancers
Nivolumab plus chemotherapy improved overall survival.
Immunotherapy, Chemotherapy Combination Improves Survival in Advanced Esophageal Cancer
Researchers have identified a potentially new first-line treatment option for patients with advanced or metastatic esophageal squamous cell carcinoma.
Update Supports Adjuvant Nivolumab as Standard Care in Resected Esophageal or Gastroesophageal Junction Cancer
Adjuvant nivolumab prolonged distant metastasis-free survival.
Electronic Monitoring May Improve Symptom Management in Cancer Patients Receiving Chemotherapy
An electronic monitoring system improved physical well-being and self-efficacy scores.
Nongenetic Risk Factors for Colorectal Cancer May Differ by Disease Onset, Subsite
Some nongenetic risk factors for late-onset colorectal cancer may not be relevant for early-onset disease.
PARP Inhibitors Increase the Risk of Pneumonitis in Clinical Trials and in Practice
Patients treated with PARP inhibitors in clinical trials had a nearly 3-fold higher risk of pneumonitis than patients in control arms.
Radiotherapy Effective for H Pylori–Independent Gastric MALT
Radiation therapy alone was highly effective for the treatment of Helicobacter pylori–independent gastric mucosa-associated lymphoid tissue lymphoma.
Family History of Polyps Raises Colorectal Cancer Risk
Having a first-degree relative with colorectal polyps may increase a person’s risk of developing colorectal cancer, indicating that earlier screening is warranted.
Pembrolizumab May Improve Health-Related Quality of Life in Metastatic Colorectal Cancer
Health-related quality of life tended to improve over time with pembrolizumab but not with chemotherapy.
Patients With Comorbidities Are More Likely to Undergo Colorectal Cancer Screening
Patients without comorbidities were less likely to undergo screening for colorectal cancer than patients with comorbidities.
High Body Mass Index Is a Risk Factor for Gallbladder and Biliary Tract Cancer Mortality
A decrease in obesity rates may reduce the burden of gallbladder and biliary tract cancer worldwide, according to the results of a study.
Cancer Diagnoses Increase at Age 65, Decrease Immediately Afterward
The largest increase in cancer diagnosis at age 65 years was in stage I for all breast cancer, colon cancer, prostate cancer, and lung cancer.
Outcomes Remain Poor for Colorectal Cancer Patients with Brain Metastases
A retrospective cohort study investigated the incidence of and risk factors for brain metastases in patients with colorectal cancer.
Neoadjuvant Chemotherapy With FOLFIRINOX Followed by Chemoradiotherapy Significantly Prolongs Disease-Free Survival in Stage T3 or T4 Rectal Cancer
The trial found that the combination improved outcomes in patients with locally advanced rectal cancer compared with standard chemoradiotherapy, surgery, and adjuvant chemotherapy.
Adjuvant Nivolumab Improved DFS in Esophageal and GEJ Cancers
Residual pathologic disease often remains after neoadjuvant chemotherapy and resection in patients with esophageal or GEJ cancers, and these patients have a high risk of recurrence.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Expertscape
Loading... 
Loading...